Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report
Manreet Randhawa, Gregory Gaughran, Christine Archer, Sayed Ali, Desmond Yip, Department of Medical Oncology, Canberra Region Cancer Centre, The Canberra Hospital, Canberra, ACT 2605, Australia
Paul Pavli, Department of Gastroenterology, The Canberra Hospital, Canberra, ACT 2605, Australia
Paul Pavli, Adrienne Morey, Sayed Ali, Desmond Yip, ANU Medical School, Australian National University, Canberra, ACT 2601, Australia
Adrienne Morey, Department of Anatomical Pathology, The Canberra Hospital, Canberra, ACT 2605, Australia
Author contributions: Randhawa M, Gaughran G and Archer C contributed equally to this work and wrote the paper; Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S and Yip D were involved in care of this patient and review and revision of this paper.
Informed consent statement: Informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016) and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Desmond Yip, FRACP, MBBS, Clinical Director, Professor, Department of Medical Oncology, Canberra Region Cancer Centre, The Canberra Hospital, Yamba Drive, Garran, Canberra, ACT 2605, Australia. email@example.com
Telephone: +61-2-51242220 Fax: +61-2-51244266
Received: February 27, 2019
Peer-review started: February 27, 2019
First decision: April 11, 2019
Revised: July 22, 2019
Accepted: September 5, 2019
Article in press: September 5, 2019
Published online: October 24, 2019